KR20220080102A - B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 - Google Patents

B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 Download PDF

Info

Publication number
KR20220080102A
KR20220080102A KR1020227011839A KR20227011839A KR20220080102A KR 20220080102 A KR20220080102 A KR 20220080102A KR 1020227011839 A KR1020227011839 A KR 1020227011839A KR 20227011839 A KR20227011839 A KR 20227011839A KR 20220080102 A KR20220080102 A KR 20220080102A
Authority
KR
South Korea
Prior art keywords
ser
gly
prt
homo sapiens
tyr
Prior art date
Application number
KR1020227011839A
Other languages
English (en)
Korean (ko)
Inventor
차오 왕
미첼 누센즈웨이그
Original Assignee
더 락커펠러 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 락커펠러 유니버시티 filed Critical 더 락커펠러 유니버시티
Publication of KR20220080102A publication Critical patent/KR20220080102A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227011839A 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 KR20220080102A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (1)

Publication Number Publication Date
KR20220080102A true KR20220080102A (ko) 2022-06-14

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011839A KR20220080102A (ko) 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법

Country Status (7)

Country Link
US (1) US20220315645A1 (ja)
EP (1) EP4021503A4 (ja)
JP (1) JP2022547551A (ja)
KR (1) KR20220080102A (ja)
CN (1) CN114728066A (ja)
CA (1) CA3154556A1 (ja)
WO (1) WO2021050954A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500515A (ja) * 1986-06-20 1989-02-23 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1848740A1 (en) * 2005-01-14 2007-10-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Monoclonal antibodies that bind or neutralize hepatitis b virus
WO2011146514A2 (en) * 2010-05-17 2011-11-24 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
US9512201B2 (en) * 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
EP3519436A4 (en) * 2016-09-30 2020-09-09 Baylor College of Medicine TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY

Also Published As

Publication number Publication date
JP2022547551A (ja) 2022-11-14
CN114728066A (zh) 2022-07-08
EP4021503A1 (en) 2022-07-06
US20220315645A1 (en) 2022-10-06
WO2021050954A1 (en) 2021-03-18
EP4021503A4 (en) 2024-02-14
CA3154556A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP7171809B2 (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
Li et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections
AU2020294246B2 (en) Antibodies, uses & methods
Hehle et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
JP2019528050A (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
WO2013185558A1 (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
AU2016322814A1 (en) Polyomavirus neutralizing antibodies
CN113544148A (zh) 中和乙型肝炎病毒的抗体和其用途
JP2016504015A (ja) Ｂ型肝炎ウイルスに結合し、かつ中和することができるヒト結合分子およびその使用
KR20220080102A (ko) B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법
KR20220063188A (ko) B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법
Kim et al. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
Wang et al. Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity
WO2023287352A9 (en) Anti-hbv antibodies and uses thereof
TW202204396A (zh) 抗hbv抗體及使用方法
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
Chan et al. Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus